A century ago, Koch (7) was one of the first to demonstrate a connection between a laboratory observation (in his time at the microbiologic level) and a human disease. In our own time, many talented investigators face the similar challenge of demonstrating a relationship between changes observed at the molecular level and human disease processes. The nm23 gene stands as a paradigm both of how far we have come and how far we have yet to go. As is now well known, the nm23 gene was discovered by virtue of its decreased expression in murine melanoma cell lines of high metastatic potential (2). Its import to human disease was established by seminal studies that demonstrated an inverse relationship between nm23 transcript expression and lymph node metastasis or poor prognosis of human breast cancer (3-6). Since that time, little has remained simple.
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As we learn more about the nm23 gene, it has become increasingly difficult to determine the optimal nm23-related parameter for measurement in studies that compare alterations of nm23 with altered metastatic potential. Complexity first arises because there are two highly homologous human nm23 alleles, HI and H2 (7), which cross-react with both DNA probes and most antibodies. Second, while these two alleles encode the subunits of a highly conserved nucleoside diphosphate (NDP) kinase (8), this kinase activity does not correlate with the metastasis-suppression activity of the nm-23 gene (9,10). Complexity is further added by the observation that the Nm23-H2 protein bears a second activity as a transcription factor that transactivates the c-myc promoter (77). Moreover, the Nm23-Hl and Nm23-H2 proteins localize to the cytoplasmic, nuclear, and membrane compartments (12,13) without indication, as yet, of which location is important for metastasis-suppression activity. In addition, Nm23 proteins undergo a post-translational phosphorylation (70) in which the effects on the localization and functional activities of the protein remain to be elucidated. Last, as discussed below, recent advances in tumor biology demonstrate that findings such as nm23 gene deletion or mutation are not, by themselves, sufficient to prove a causal role for these alterations in the genesis of the tumors in which they are found.
Given these complexities, it is good fortune that in at least two systems (murine melanoma and human breast cancer), wellconducted experiments have continued to build a strong argument for the role of the nm23 gene as a metastasis suppressor. Elegant work by Leone et al. (14) has shown in the murine melanoma model that the transfected nm23-l gene can suppress metastasis and that metastasis suppression correlates best with Nm23 phosphoprotein levels, rather than with NDP kinase levels (70). An important addition is the demonstration of similar metastasis suppression in the MDA-MB-435 human breast cancer cell line (75) . Work in these model systems compares well with observations that reduced Nm23-Hl expression correlates positively with presence of breast cancer lymph node metastasis in humans (16). We now need a clinical study of sufficient power to separate the role of the nm23 gene as a prognostic marker in breast cancer that is independent of the many other candidate markers and an understanding of the mechanism by which the nm23 gene acts.
The article by Howlett et al. (7 7) in this issue of the Journal marks a step forward in answering the latter question by demonstrating that, when cultured with reconstituted basement membrane, nm23 gene-transfected MDA-MB-435 cells express basement membrane components (type IV collagen and laminin) and show other characteristics of breast epithelial differentiation. These observations fit well with previous observations in these cells and in metastatic murine melanoma cells that nm23 gene transfection abolishes the paradoxical transforming growth factor-P (TGF-p) stimulation of soft-agar colony growth (14,15). These experiments underline the importance of Nm23 protein in breast cancer and argue for the development of a standard Nm23 protein detection methodology suitable for use in multicenter clinical trials of sufficient power to settle the prognostic role of the nm23 gene.
In contrast to breast cancer, understanding the role of the nm23 gene in other human malignancies is confounded by the high levels of nm23 gene transcripts and/or Nm23 protein expressed in some metastatic tumors including prostate (18), lung (19), thyroid (20), and colon (2122) carcinomas. These observations are consistent with reports that, in some cell lines, Nm23 protein expression serves as a proliferation marker (18,23), as might be expected for either an NDP kinase or a myc transcription factor. Study of clinical samples in our laboratory has shown induction of Nm23-Hl and Nm23-H2 transcripts in colon cancers, without evidence of gene mutation as judged by ribonuclease protection (21, 22) . In colon cancer cell line models, Radinsky et al. (24) showed no association between nm23 gene expression and metastatic competence. Production of ample wild-type message in colon tumors suggests that the nm23-Hl gene probably is not the target of the 17q deletion, which deletes the nm23 gene in some metastatic colon cancers (25,26). While it is tempting to posit the existence of a novel colon cancer suppressor gene as the target of this 17q deletion, such speculation must be tempered by the previous observations by Vogelstein et al. (27) of a high rate (median, 20%) of random allelic deletions in late-stage colon cancers. Similarly, reports of rare nm23-Hl mutations in colon cancer (28) must be judged against the demonstration that some colon cancers arise through a "mutator" pathway (29 -35) . In such mutator colon cancers, mutations in random genes early in tumor formation might serve as markers of the tumor's clonal evolution rather than as clear evidence of oncogenic involvement of the mutated allele. One report (36) has suggested that Nm23 protein expression is reduced in colon hepatic but not in lymph node metastases. While intriguing, such reports need to be judged with the caution that retrospective analysis of clinical data will often define patient subsets that seemingly correlate with a given marker. However, such correlations can be validated only when repeated prospectively with a second independent patient population. Similar interest and caution pertain to the recent observation that nuclear Nm23 protein staining, as opposed to cytoplasmic staining, identifies thyroid cancers that have a poor prognosis (37) . Future studies of possible alterations in Nm23 protein compartmentalization or phosphorylation in colon tumors metastatic to lymph nodes or liver remain necessary and of interest. Reports of nm23 gene mutations in advanced-stage childhood neuroblastoma (38, 39) are the most intriguing suggestion that the nm23 gene may be involved in tumor progression in malignancies in which it is expressed. We await with interest future determination of the functional properties of these mutations.
In overview, we note that, with the possible exception of p53, most currently defined tumor suppressor genes and oncogenes show clear tissue restriction in the malignancies with which they are associated. It is perhaps too much to expect that alterations in a single gene, even one with as intriguing a group of properties as nm23, will be a key event in all tumor types. Accordingly, the most exciting feature of the recent studies by Howlett et al. (17) is that, by connecting Nm23 protein to normal cellular functions such as basement membrane elaboration and response to TGF-P, these studies shed light on pathways that may well be of key importance in the metastatic process across diverse human tumor types. If you plan to show the tape at a meeting of health professionals or other interested persons, we would be happy to arrange for a staff member to attend the showing and conduct a follow-up question and answer session. To schedule a presentation or order tapes, call Molly Matthews at (301) 951-1104. 
